A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).

被引：0
|
作者：
Hendifar, Andrew Eugene
Kim, Sungjin
Tighiouart, Mourad
Hautamaki, Emily
Kim, Haesoo
Ng, Camille
Liu, Jar-Yee
Scher, Kevin S.
Klempner, Samuel J.
Placencio-Hickok, Veronica
Gresham, Gillian
Gong, Jun
机构：
[1] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, West Hollywood, CA USA
[4] Tower Hematol Oncol Med Grp, Beverly Hills, CA USA
[5] Angeles Clin & Res Inst, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4634
引用
收藏
页数：2
相关论文
共 50 条
  • [31] THE ROLE OF FOLINIC ACID IN COMBINATION WITH 5-FLUOROURACIL IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    WILKE, H
    HARSTRICK, A
    SEEBER, S
    ONKOLOGIE, 1995, 18 (01): : 65 - 67
  • [32] Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:: results of a randomized phase II study
    Pozzo, C
    Barone, C
    Szanto, J
    Padi, E
    Pesche, C
    Bükki, J
    Gorbunova, V
    Valvere, V
    Zaluski, J
    Biakhov, M
    Zuber, E
    Jacques, C
    Bugat, R
    ANNALS OF ONCOLOGY, 2004, 15 (12) : 1773 - 1781
  • [33] A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Chiesa, Matteo Dalla
    Buti, Sebastiano
    Tomasello, Gianluca
    Negri, Federica
    Buononato, Massimo
    Brunelli, Antonio
    Lazzarelli, Silvia
    Brighentl, Matteo
    Donati, Gianvito
    Passalacqua, Rodolfo
    TUMORI, 2007, 93 (03) : 244 - 247
  • [34] A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma
    Hsue, V
    Wong, CS
    Moore, M
    Erlichman, C
    Cummings, BJ
    MacLeod, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02): : 445 - 450
  • [35] Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study.
    Creaven, PJ
    Javle, MM
    Pendyala, L
    Smith, P
    Noel, DC
    Iyer, RV
    Lawrence, DD
    Rustum, YM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 157S - 157S
  • [36] Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: A prospective comparative study
    Tsavaris, N
    Tentas, K
    Tzivras, M
    Kosmas, C
    Kalachanis, N
    Katsikas, M
    Dimitrakopoulos, A
    Papastratis, G
    Macheras, A
    Karatzas, G
    Sechas, M
    JOURNAL OF CHEMOTHERAPY, 1998, 10 (04) : 331 - 337
  • [37] Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)
    Gubanski, M.
    Glimelius, B.
    Lind, P. A.
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [38] Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)
    M. Gubanski
    B. Glimelius
    P. A. Lind
    Medical Oncology, 2014, 31
  • [39] Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
    Yamazaki, K.
    Yeshlno, T.
    Yamaguchi, K.
    Boku, N.
    Machlda, N.
    Onozawa, Y.
    Asayama, M.
    Doi, T.
    Ohtsu, A.
    Aoyama, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] Oxaliplatin plus 5-fluorouracil and folinic acid (off) in gemcitabine-pretreated advanced pancreatic cancer: A phase ii study
    El-Hadaad H.A.
    Wahba H.A.
    Journal of Gastrointestinal Cancer, 2013, 44 (3) : 313 - 317
12345